Skip to main content

Leadership

2014 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/17/14Emergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum AntibioticsDownload PDFPrinter Friendly Version
11/24/14Emergent BioSolutions to Webcast Presentation at 25th Annual Oppenheimer Healthcare ConferenceDownload PDFPrinter Friendly Version
11/10/14Emergent BioSolutions Seeks Expanded BioThrax Label; Submits FDA Application for Post-Exposure ProphylaxisDownload PDFPrinter Friendly Version
11/06/14Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial ResultsDownload PDFPrinter Friendly Version
10/20/14Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare ConferenceDownload PDFPrinter Friendly Version
10/09/14Emergent BioSolutions to Release Third Quarter 2014 Financial Results and Conduct a Conference Call on November 6, 2014Download PDFPrinter Friendly Version
09/23/14Emergent BioSolutions Initiates Final Pivotal Study to Support Licensure of BioThrax at Large ScaleDownload PDFPrinter Friendly Version
09/08/14Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation Anthrax VaccineDownload PDFPrinter Friendly Version
08/19/14Emergent BioSolutions and MorphoSys Sign License Agreement to Co-Develop and Commercialize Prostate Cancer Drug Candidate ES414Download PDFPrinter Friendly Version
08/08/14U.S. Government Exercises Contract Options Valued at $18.9M for Emergent BioSolutions' Vaccinia Immune Globulin Intravenous ProgramDownload PDFPrinter Friendly Version
08/07/14Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2014Download PDFPrinter Friendly Version
08/07/14Emergent BioSolutions Submits Biologics License Application to FDA for Anthrax Immune Globulin Intravenous (Human)Download PDFPrinter Friendly Version
07/10/14Emergent BioSolutions to Release Second Quarter 2014 Financial Results and Conduct a Conference Call on August 7, 2014Download PDFPrinter Friendly Version
05/29/14Emergent BioSolutions to Participate in June 2014 Investor ConferencesDownload PDFPrinter Friendly Version
05/15/14Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 22, 2014 at 9:00 AM Eastern; Webcast Will Be AvailableDownload PDFPrinter Friendly Version
05/08/14Emergent BioSolutions Reports First Quarter 2014 Financial ResultsDownload PDFPrinter Friendly Version
04/23/14Emergent BioSolutions to Release First Quarter 2014 Financial Results and Conduct a Conference Call on May 8, 2014Download PDFPrinter Friendly Version
04/22/14Emergent BioSolutions and FDA Finalize Comparability Protocols Enabling Manufacturing of BioThrax Consistency Lots in Building 55Download PDFPrinter Friendly Version
04/21/14Emergent BioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax DiseaseDownload PDFPrinter Friendly Version
04/17/14Emergent BioSolutions to Participate in May 2014 Investor ConferencesDownload PDFPrinter Friendly Version
04/16/14Emergent BioSolutions Successfully Completes Pivotal Clinical Study to Support Expanded Indication for BioThraxDownload PDFPrinter Friendly Version
03/06/14Emergent BioSolutions Reports Financial Results for 2013Download PDFPrinter Friendly Version
03/03/14Emergent BioSolutions to Release Fourth Quarter and Full Year 2013 Financial Results and Conduct a Conference Call on March 6, 2014Download PDFPrinter Friendly Version
02/21/14Emergent BioSolutions Completes Acquisition of Cangene CorporationDownload PDFPrinter Friendly Version
02/03/14Emergent BioSolutions to Webcast Presentations at February and March 2014 Investor ConferencesDownload PDFPrinter Friendly Version
01/29/14Emergent BioSolutions Announces Completion of $250 Million Convertible Senior Notes OfferingDownload PDFPrinter Friendly Version
01/28/14Emergent BioSolutions Announces Expiration of the Hart-Scott-Rodino Waiting Period for Emergent’s Acquisition of Cangene CorporationDownload PDFPrinter Friendly Version
01/27/14Emergent BioSolutions Announces $35 Million Option Exercised by the Initial Purchasers of the Company’s Convertible Senior NotesDownload PDFPrinter Friendly Version
01/23/14Emergent BioSolutions Announces Pricing of Offering of $215 Million of 2.875% Convertible Senior NotesDownload PDFPrinter Friendly Version
01/22/14Emergent BioSolutions Announces Proposed Offering of $200 Million Convertible Senior NotesDownload PDFPrinter Friendly Version
01/13/14Emergent BioSolutions Announces Preliminary 2013 Financial Results and Provides 2014 ForecastDownload PDFPrinter Friendly Version